Phaseline

Targets › IFNA2

IFNA2 (Interferon alpha-2): drug programs, companies and trials

1 program from 1 company in 5 trials: 4 Phase 3, 1 Phase 1; Oncology; next expected readout Jun 2028.

Produced by macrophages, IFN-alpha have antiviral activities. (UniProt, P01563)

Open in Phaseline: the race on IFNA2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ferring PharmaceuticalsNadofaragene Firadenovec
Interferon alpha-2 exogenous gene
IFNA2Phase 3Non-muscle Invasive Bladder Cancer With Carcinoma in Situ; Intermediate Risk Non-Muscle Invasive Bladder Cancer; Bladder Cancer; Low-grade Upper Tract Urothelial Carcinoma …Jun 2028

Conditions

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ (1) Intermediate Risk Non-Muscle Invasive Bladder Cancer (1) Bladder Cancer (1) Low-grade Upper Tract Urothelial Carcinoma (1) Non-Muscle Invasive Bladder Cancer (1)

Modalities

other (1)

Companies

Ferring Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.